Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
The Business Journals24d
Lilly to pay $2.5B for Boston biotech's lead cancer drug
Scorpion Therapeutics Inc. is selling STX-478, its lead drug for breast cancer and other advanced solid tumors that is currently in a Phase 1/2 clinical trial. Lilly (NYSE: LLY) will pay Scorpion ...
STAT24d
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal
As part of the deal, Lilly is buying the privately held Scorpion, but the startup is spinning out a new company that will hold onto its employees and drug candidates not focused on PI3Kα.